The Latest Breaking News on After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Donanemab was shown in a late-stage trial to slow cognitive decline more than a third

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

A new drug could slow the pace of Alzheimer’s. Three people with experience of the disease explain their story and their hopes

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed. 

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

New drug donanemab appears to slow decline associated with Alzheimer’s

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.